Finanzen von Medifast Inc (MED)MEDMedifast Inc

Medifast Inc (MED) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Take Shape For Life, accounting for 88.0% of total sales, equivalent to $68.61M. Other significant revenue streams include Medifast and Medifast Weight Control Centers- Franchise. Understanding this composition is critical for investors evaluating how MED navigates market cycles within the Food Processing industry.

Evaluating the bottom line, Medifast Inc maintains a gross margin of 69.90%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -5.66%, while the net margin is -4.06%. These profitability ratios, combined with a Return on Equity (ROE) of -12.42%, provide a clear picture of how effectively MED converts its operational activities into shareholder value.

In the context of the broader market, MED competes directly with industry leaders such as JLHL and DOYU. With a market capitalization of $127.91M, it holds a significant position in the sector. When comparing efficiency, MED's gross margin of 69.90% stands against JLHL's 15.65% and DOYU's 16.21%. Such benchmarking helps identify whether Medifast Inc is trading at a premium or discount relative to its financial performance.

Medifast's recent financial performance shows a revenue of $76.4 million in Q2 2026, exceeding market expectations by $3.7 million, indicating a recovery trend. The gross margin stands at 69.90%, which is relatively strong, although it has seen a decline from previous quarters.